DepYmed
DepYmed is a clinical-stage pharmaceutical company developing orally bioavailable small molecule PTP1B inhibitors and copper chelating compounds targeting cancer, Rett Syndrome, Wilson Disease, and neurodegenerative diseases. Its lead asset, DPM-1003, received FDA Phase 1 clearance in March 2024.
- Company typePrivate
- Founded2014
- HeadquartersFarmingdale, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What DepYmed does
DepYmed, Inc. is a clinical-stage pharmaceutical company headquartered at 3 Bioscience Park Drive, Farmingdale, New York, developing two orally bioavailable small molecule therapeutic platforms: novel selective inhibitors of PTP1B (protein tyrosine phosphatase 1B) and a portfolio of small molecules with copper chelating properties. The company is advancing candidates for cancer, rare genetic diseases including Rett Syndrome and Wilson Disease, and neurodegenerative conditions including Alzheimer's disease. Its lead asset, DPM-1003—an orally bioavailable PTP1B inhibitor—received U.S. FDA clearance in March 2024 to initiate a Phase 1 clinical trial in Rett Syndrome.
The company's scientific foundation is reinforced through a research collaboration with the Tonks Lab at Cold Spring Harbor Laboratory, led by Professor Nicholas Tonks, whose group published proof-of-concept data in PNAS showing that PTP1B inhibition enhances microglial clearance of amyloid-beta plaques and improves memory in Alzheimer's mouse models. DepYmed is building a broader library of PTP1B inhibitors it intends to position for metabolic, inflammatory, and neurodegenerative diseases, and is developing copper chelating compounds as potential therapeutics for Wilson Disease and cancer.
DepYmed is a privately held, pre-revenue company with approximately $11.5 million in cumulative disclosed funding across seed and early-stage rounds led primarily by Topspin Fund and supported by Accelerate New York Seed Fund and Accelerate Long Island. The firm employs 11–50 people, executes an enterprise field sales / partner-driven GTM appropriate to a clinical-stage developer, and anticipates generating future revenue through pharmaceutical product sales following regulatory approval. Leadership is anchored by Andreas Grill, Founder, President & CEO.
DepYmed firmographics
Firmographics- Name
- DepYmed
- Legal name
- DepYmed, Inc.
- Website
- https://depymedinc.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DepYmed is a clinical-stage pharmaceutical company developing orally bioavailable small molecule PTP1B inhibitors and copper chelating compounds targeting cancer, Rett Syndrome, Wilson Disease, and neurodegenerative diseases. Its lead asset, DPM-1003, received FDA Phase 1 clearance in March 2024.
- Ownership category
- akta.pro rank
DepYmed industry classification
Industry- Product category
- Clinical-Stage Pharmaceutical Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where DepYmed is headquartered
LocationHeadquarters
- HQ city
- Farmingdale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
DepYmed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Therapeutic Development and Commercialization: DepYmed is a clinical-stage pharmaceutical company developing novel therapeutics. The company is advancing PTP1B inhibitors and copper chelating compounds through clinical trials with the goal of commercializing treatments for rare diseases and cancer. Revenue model is expected to come from pharmaceutical product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
DepYmed product offering
Product offeringCore offering
DepYmed is a clinical-stage pharmaceutical company developing orally bioavailable small-molecule therapeutics built on two proprietary platforms: PTP1B (protein tyrosine phosphatase 1B) inhibitors for cancer, rare diseases (including Rett Syndrome), and neurodegenerative conditions, and copper chelating small molecules for Wilson Disease and cancer. Its lead asset DPM-1003, an orally bioavailable PTP1B inhibitor, received U.S. FDA clearance in March 2024 to begin a Phase 1 clinical trial for the treatment of Rett Syndrome.
Product overview
DepYmed is a pharmaceutical company developing novel therapeutics based on two core technology platforms: PTP1B (protein tyrosine phosphatase 1B) inhibitors and copper chelating small molecules. The company's lead product is DPM-1003, an orally bioavailable small molecule PTP1B inhibitor that has received FDA clearance for Phase 1 clinical trials in Rett Syndrome. DepYmed is advancing these two therapeutic approaches into clinical trials for multiple indications including Rett Syndrome, cancer, and Wilson Disease, while also building a library of PTP1B inhibitors for other metabolic, inflammatory, and neurodegenerative diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- DPM-1003 (PTP1B inhibitor for Rett Syndrome) Orally bioavailable small-molecule PTP1B inhibitor being advanced into Phase 1 clinical trials for the treatment of Rett Syndrome, a rare genetic neurological disorder with no existing cure. FDA clearance to proceed was received in March 2024.
- PTP1B Inhibitor Library Library of novel, selective PTP1B (protein tyrosine phosphatase 1B) inhibitors under development as therapeutics for cancer, rare diseases, and neurodegenerative conditions, including Alzheimer's disease, with broader potential across metabolic, inflammatory, and neurodegenerative indications.
- Copper Chelating Small Molecules Portfolio of novel small molecules with copper chelating properties being developed as potential therapeutic agents for Wilson Disease and cancer indications.
Quantifiable outcome
- PTP1B inhibition improves learning and memory in Alzheimer's disease mouse model by enhancing microglial function to clear amyloid-beta plaques
Companies that use DepYmed
Customer profileSegments4 records
Ideal customer profiles2 records
DepYmed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
DepYmed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cold Spring Harbor Laboratory (Tonks Lab)coreThe Tonks lab at Cold Spring Harbor Laboratory, led by Professor Nicholas Tonks, is collaborating with DepYmed, Inc. to develop PTP1B inhibitors as potential therapeutics. The collaboration has identified PTP1B as a validated therapeutic target for Alzheimer's disease, with research published in the Proceedings of the National Academy of Sciences demonstrating that inhibiting PTP1B in mice improved learning and memory by enhancing microglial function to clear amyloid-beta plaques. The goal is to combine PTP1B inhibitors with existing approved drugs to slow Alzheimer's progression and improve patient quality of life.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
DepYmed competitors and assessment
Company assessmentDirect peers
- Orphalan: Specialty pharmaceutical company developing and commercializing Cuvrior (trientine tetrahydrochloride) for Wilson Disease. Direct comparable as a Wilson Disease-focused therapeutic developer with copper chelation mechanism overlap with DepYmed's copper chelator program.
- Soleno Therapeutics: Clinical-stage biopharmaceutical company focused on rare diseases, with DCCR for Prader-Willi Syndrome as lead asset. Comparable as a clinical-stage rare disease developer with similar small-molecule approach and resource profile.
- Acer Therapeutics: Clinical-stage rare disease biopharmaceutical company developing therapeutics for underserved genetic disorders. Comparable as a small rare disease biotech with similar stage, size profile, and indication focus.
- Mirum Pharmaceuticals: Commercial-stage rare disease company focused on cholestatic liver diseases including conditions addressed by copper-related mechanisms. Comparable as a focused rare disease therapeutics developer with overlapping disease biology in Wilson Disease-adjacent indications.
- Taysha Gene Therapies: Clinical-stage gene therapy company developing TSHA-102 for Rett Syndrome, the same lead indication as DepYmed's DPM-1003. Directly comparable as a focused rare pediatric disease therapeutic developer at similar development stage.
- Anavex Life Sciences: Clinical-stage biopharmaceutical company developing blarcamesine for Rett Syndrome and other neurological rare diseases. Directly comparable as a small-molecule developer targeting the same rare neurological indication.
Broad incumbents
- Travere Therapeutics: Established rare disease biopharmaceutical company with multiple approved and clinical-stage assets across rare metabolic and neurological disorders. Comparable as a broader rare disease therapeutics developer with overlapping Wilson Disease and metabolic disease focus.
- BioMarin Pharmaceutical: Major rare disease biopharmaceutical company with multiple approved enzyme replacement and small molecule therapies. Comparable as an established rare disease commercial player addressing similar genetic and metabolic disorders.
- Alexion (AstraZeneca Rare Disease): Established rare disease division of AstraZeneca that previously developed ALXN1840 (Wilson Disease asset) and has deep rare neurological disease expertise. Comparable as a large rare disease incumbent with direct Wilson Disease and neurological rare disease overlap.
- Ultragenyx Pharmaceutical: Established rare and ultra-rare disease biopharmaceutical company with multiple approved products across metabolic, neurological, and skeletal rare diseases. Comparable as a broader rare disease therapeutic platform with significant overlap in target indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
DepYmed social profiles
Digital presenceDepYmed financial estimates
Financial estimateRevenue estimate
Valuation estimate
DepYmed leadership team
Management profileNumber of profiles
Profiles1 record
DepYmed funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DepYmed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DepYmed
What does DepYmed do?
DepYmed is a clinical-stage pharmaceutical company developing orally bioavailable small-molecule therapeutics built on two proprietary platforms: PTP1B (protein tyrosine phosphatase 1B) inhibitors for cancer, rare diseases (including Rett Syndrome), and neurodegenerative conditions, and copper chelating small molecules for Wilson Disease and cancer. Its lead asset DPM-1003, an orally bioavailable PTP1B inhibitor, received U.S. FDA clearance in March 2024 to begin a Phase 1 clinical trial for the treatment of Rett Syndrome.
Is DepYmed a public or private company?
DepYmed is a private company. It is classified as venture growth investor backed and is currently operating.
When was DepYmed founded?
DepYmed was founded in 2014. It employs 1 to 10 people.
Where is DepYmed based?
DepYmed is headquartered in Farmingdale, United States, in the North America region.
How does DepYmed make money?
One revenue line is on record: therapeutic Development and Commercialization.
Who are DepYmed's main competitors?
Direct peers on record are Orphalan, Soleno Therapeutics, Acer Therapeutics, Mirum Pharmaceuticals, Taysha Gene Therapies and Anavex Life Sciences. Broad incumbents are Travere Therapeutics, BioMarin Pharmaceutical, Alexion (AstraZeneca Rare Disease) and Ultragenyx Pharmaceutical.
Does DepYmed have an API?
No public API is recorded for DepYmed.
What industry is DepYmed in?
DepYmed's product category is Clinical-Stage Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714.